[go: up one dir, main page]

CY1118492T1 - Φαρμακοτεχνικες μορφες εμβολιου norovirus - Google Patents

Φαρμακοτεχνικες μορφες εμβολιου norovirus

Info

Publication number
CY1118492T1
CY1118492T1 CY20171100109T CY171100109T CY1118492T1 CY 1118492 T1 CY1118492 T1 CY 1118492T1 CY 20171100109 T CY20171100109 T CY 20171100109T CY 171100109 T CY171100109 T CY 171100109T CY 1118492 T1 CY1118492 T1 CY 1118492T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical forms
vlps
vaccine pharmaceutical
norovirus vaccine
norovirus
Prior art date
Application number
CY20171100109T
Other languages
English (en)
Inventor
Charles Richardson
Thomas S Vedvick
Thomas R Foubert
William T Tino
Original Assignee
Takeda Vaccines, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39268804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118492(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines, Inc. filed Critical Takeda Vaccines, Inc.
Publication of CY1118492T1 publication Critical patent/CY1118492T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε αντιγονικές και εμβολίου συνθέσεις που περιλαμβάνουν αντιγόνα Norovirus και ανοσοενισχυτικά, ειδικότερα, μείγματα μονοδύναμων VLPs και μείγματα πολυδύναμων VLPs και σε μία μέθοδο για την παρασκευή τόσο μονοδύναμων όσο και πολυδύναμων VLPs, με τα VLPs να περιέχουν πρωτεΐνες καψιδίου από μια ή περισσότερες γενο-ομάδες Norovirus.
CY20171100109T 2006-09-29 2017-01-25 Φαρμακοτεχνικες μορφες εμβολιου norovirus CY1118492T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84791206P 2006-09-29 2006-09-29
US97339207P 2007-09-18 2007-09-18
EP07853688.5A EP2066354B1 (en) 2006-09-29 2007-09-28 Norovirus vaccine formulations

Publications (1)

Publication Number Publication Date
CY1118492T1 true CY1118492T1 (el) 2017-07-12

Family

ID=39268804

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100109T CY1118492T1 (el) 2006-09-29 2017-01-25 Φαρμακοτεχνικες μορφες εμβολιου norovirus

Country Status (17)

Country Link
US (8) US7955603B2 (el)
EP (4) EP2601969B1 (el)
JP (3) JP5476544B2 (el)
KR (1) KR101515489B1 (el)
AU (1) AU2007303608B2 (el)
CA (1) CA2664157C (el)
CY (1) CY1118492T1 (el)
DK (3) DK2601969T3 (el)
ES (3) ES2577833T3 (el)
HK (1) HK1184057A1 (el)
HU (2) HUE028978T2 (el)
LT (1) LT2601970T (el)
PL (2) PL2601970T3 (el)
PT (1) PT2601970T (el)
SG (3) SG10201502490YA (el)
SI (1) SI2601970T1 (el)
WO (1) WO2008042789A1 (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201502490YA (en) 2006-09-29 2015-05-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
WO2008113011A2 (en) 2007-03-14 2008-09-18 Ligocyte Pharmaceuticals, Inc. Virus like particle purification
KR20100083150A (ko) * 2007-09-18 2010-07-21 리고사이트 파머슈티컬즈 인코퍼레이티드 노로바이러스에 대한 보호면역반응을 제공하는 방법
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
PL2324113T3 (pl) 2008-08-08 2018-08-31 Takeda Vaccines, Inc. Cząstki wirusopodobne zawierające złożone kapsydowe sekwencje aminokwasowe do zwiększonej reaktywności krzyżowej
WO2010111586A2 (en) * 2009-03-27 2010-09-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Mucosal immunization
US20110070260A1 (en) * 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
US9439958B2 (en) * 2009-12-23 2016-09-13 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
EP2525816A4 (en) * 2010-01-21 2013-10-02 Ligocyte Pharmaceuticals Inc PRESENTATION OF TARGETED HETEROLOGOUS ANTIGENS ON CALICIVIRUS VIRAL PSEUDO PARTICLES
CN107260689A (zh) * 2010-04-15 2017-10-20 株式会社新日本科学 用于鼻内递送的方法和组合物
AU2012244074B2 (en) * 2010-04-15 2015-01-15 Km Biologics Co., Ltd. Methods and compositions for intranasal delivery
MY170746A (en) 2011-07-11 2019-08-27 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
JOP20130186B1 (ar) * 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
US20140017257A1 (en) * 2012-07-11 2014-01-16 Xi Jiang IgY From Norovirus P Particles And Their Derivatives
WO2014100853A1 (en) * 2012-12-28 2014-07-03 Cellestis Limited A cell mediated immune response assay
US9975923B2 (en) 2013-03-15 2018-05-22 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
WO2014145245A2 (en) * 2013-03-15 2014-09-18 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
JP2015015931A (ja) 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
JP2015017065A (ja) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ノロウイルスのウイルス様粒子を含む医薬組成物
JP6479305B2 (ja) 2013-07-12 2019-03-06 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
CN105358178B (zh) 2013-07-17 2019-05-31 陶氏环球技术有限责任公司 用于施加到粘膜的包含甲基纤维素的组合物
SG10201802772YA (en) 2013-10-03 2018-05-30 Takeda Vaccines Inc Methods of detection and removal of rhabdoviruses from cell lines
WO2015093452A1 (ja) 2013-12-16 2015-06-25 武田薬品工業株式会社 マイクロニードル
AU2016317661B2 (en) 2015-08-28 2023-05-18 Ology Bioservices, Inc. Norovirus vaccine
KR101914779B1 (ko) * 2016-03-18 2018-11-02 (주)인테라 노로 바이러스 백신을 생산하기 위한 재조합 발현 벡터
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
US11833198B2 (en) 2017-03-28 2023-12-05 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same
RU2020116307A (ru) 2017-11-30 2021-12-30 Медикаго Инк. Модифицированные белки vp1 норовируса и vlp, содержащие модифицированные белки vp1 норовируса
EP3752185A1 (en) 2018-02-15 2020-12-23 Icon Genetics GmbH Immunogenic composition and vaccine for generating an immune response to norovirus
JP6713013B2 (ja) * 2018-03-06 2020-06-24 株式会社イーダブルニュートリション・ジャパン 貝類のノロウイルス不活化方法
US11759512B2 (en) 2018-07-13 2023-09-19 Medicago Inc. Modified norovirus VP1 proteins and VLPs comprising modified norovirus VP1 proteins
WO2020041192A1 (en) 2018-08-20 2020-02-27 Takeda Vaccines, Inc. Vlp formulations
WO2020061067A2 (en) * 2018-09-17 2020-03-26 Board Of Regents, The University Of Texas System Texas System Compositions and methods for treating bone injury
US11523988B2 (en) * 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
EP3698773A1 (en) 2019-02-21 2020-08-26 Università degli Studi di Parma Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination
KR20220021451A (ko) 2019-03-12 2022-02-22 아이콘 제네틱스 지엠비에이치 안정성이 향상된 노로바이러스 유사 입자
JP2022544414A (ja) * 2019-08-13 2022-10-18 アルティミューン インコーポレーティッド 治療剤の有効性及びその投与の経路
WO2022246323A1 (en) 2021-05-21 2022-11-24 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
AU2023235760A1 (en) 2022-03-18 2024-10-24 Denka Company Limited Virus-like particle containing capsid proteins connected by linker.
CN117330750A (zh) * 2023-12-01 2024-01-02 北京生物制品研究所有限责任公司 一种筛选新冠病毒早期毒种的方法和制造疫苗的方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) * 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
WO1992016543A1 (en) 1991-03-25 1992-10-01 Genelabs Incorporated NORWALK VIRUS HUMAN GASTROENTERITIS AGENT AND MOLECULAR CLONING OF CORRESPONDING cDNAs
JPH07509122A (ja) 1992-04-08 1995-10-12 ザ　ガバメント　オブ　ザ　ユナイテッド　ステイツ　オブ　アメリカ，アズ　レプリゼンテッド　バイ　ザ　セクレター，デパートメント　オブ　ヘルス　アンド　ヒューマン　サービシーズ 野生型麻疹ウイルス糖タンパク質：ワクチンおよびその検出方法
DE69405551T3 (de) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
DK0757717T3 (da) 1994-05-16 2006-09-25 Merck & Co Inc Papillomavirusvacciner
US5645051A (en) * 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) * 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
CN1259051A (zh) 1997-04-08 2000-07-05 麦克公司 稳定化后的人乳头瘤病毒制剂
CA2288129A1 (en) 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) * 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
DE69931053T2 (de) * 1998-08-14 2006-11-23 Merck & Co., Inc. Verfahren zur reinigung von menschlichen, dem papillomavirus ähnlichen partikeln.
AU770809B2 (en) 1998-12-17 2004-03-04 Merck Sharp & Dohme Corp. Synthetic virus-like particles with heterologous epitopes
WO2000045841A2 (en) 1999-02-05 2000-08-10 Merck & Co., Inc. Human papilloma virus vaccine formulations
JP4629935B2 (ja) 1999-06-22 2011-02-09 国立感染症研究所長 Ｓｒｓｖ検出キット
AU2003219760A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIO-ACTIVE MATERIALS WITH LYOPHILIZED FOAM
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
ATE521367T1 (de) 2002-06-07 2011-09-15 Kentucky Bioproc Llc Flexlibler aufbau- und darreichungs-plattform von impfstoffen
PL375306A1 (en) 2002-06-20 2005-11-28 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
WO2004075829A2 (en) 2003-01-30 2004-09-10 Chiron Corporation Adjuvanted influenza vaccine
WO2004073652A2 (en) 2003-02-20 2004-09-02 Becton Dickinson And Company Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2005032457A2 (en) 2003-07-21 2005-04-14 Boyce Thompson Institute For Plant Research, Inc. Vectors and methods for immunization against norwalk virus using transgenic plants
EP1670824A2 (en) 2003-09-24 2006-06-21 Montana State University Norovirus monoclonal antibodies and peptides
WO2005037223A2 (en) * 2003-10-15 2005-04-28 Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) * 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) * 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
WO2006044857A2 (en) 2004-10-20 2006-04-27 Acambis Inc. Vaccines against japanese encephalitis virus and west nile virus
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
RU2007129840A (ru) 2005-01-05 2009-02-20 Филадельфия Хелт Энд Эдьюкейшн Корпорейшн Д/Б/А Дрексел Юниверсити Колледж Оф Медисин (Us) Средства доставки, биологически активные вещества и вирусные вакцины
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
CN101203529A (zh) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
AU2006224529B2 (en) 2005-03-18 2012-05-24 Cytos Biotechnology Ag Cat allergen fusion proteins and uses thereof
BRPI0611336A2 (pt) 2005-06-01 2010-08-31 Dow Global Technologies Inc método para produzir uma partìcula multivalente semelhante a vìrus, partìcula multivalente semelhante a vìrus, método de aumentar a solubilidade de uma partìcula multivalente semelhante a vìrus e vacina
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスｇｉの高感度検出方法
SG10201502490YA (en) 2006-09-29 2015-05-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
CA2671629C (en) 2006-12-06 2017-08-15 Novartis Ag Vaccines including antigen from four strains of influenza virus
US8474614B2 (en) * 2007-03-14 2013-07-02 BBY Solutions Protective container for a flat screen monitor
WO2008113011A2 (en) 2007-03-14 2008-09-18 Ligocyte Pharmaceuticals, Inc. Virus like particle purification
KR20100083150A (ko) * 2007-09-18 2010-07-21 리고사이트 파머슈티컬즈 인코퍼레이티드 노로바이러스에 대한 보호면역반응을 제공하는 방법
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
PL2324113T3 (pl) 2008-08-08 2018-08-31 Takeda Vaccines, Inc. Cząstki wirusopodobne zawierające złożone kapsydowe sekwencje aminokwasowe do zwiększonej reaktywności krzyżowej
JP2012515752A (ja) 2009-01-22 2012-07-12 ファーマシーネ，インコーポレイテッド 安定なワクチン組成物とその使用方法
EA201171032A1 (ru) 2009-02-10 2012-02-28 Новартис Аг Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
EP2525816A4 (en) 2010-01-21 2013-10-02 Ligocyte Pharmaceuticals Inc PRESENTATION OF TARGETED HETEROLOGOUS ANTIGENS ON CALICIVIRUS VIRAL PSEUDO PARTICLES
MX352324B (es) 2010-05-26 2017-11-17 Selecta Biosciences Inc Star Vacunas multivalentes de nanovehiculos sinteticos.
MY170746A (en) 2011-07-11 2019-08-27 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات

Also Published As

Publication number Publication date
CA2664157C (en) 2015-12-01
PL2601970T3 (pl) 2017-07-31
DK2601970T3 (en) 2017-02-06
EP2066354A1 (en) 2009-06-10
PT2601970T (pt) 2017-02-02
US20120156243A1 (en) 2012-06-21
EP2066354B1 (en) 2013-04-17
SI2601970T1 (sl) 2017-04-26
HK1184057A1 (zh) 2014-01-17
US20140286994A1 (en) 2014-09-25
SG10201502490YA (en) 2015-05-28
JP2010505766A (ja) 2010-02-25
EP2601970A1 (en) 2013-06-12
DK2601969T3 (en) 2016-04-18
HUE032422T2 (en) 2017-09-28
AU2007303608A1 (en) 2008-04-10
EP2601969B1 (en) 2016-03-30
JP2013234188A (ja) 2013-11-21
KR101515489B1 (ko) 2015-04-30
US20120093861A1 (en) 2012-04-19
US10512682B2 (en) 2019-12-24
ES2420136T3 (es) 2013-08-22
US9272028B2 (en) 2016-03-01
US20130273105A1 (en) 2013-10-17
LT2601970T (lt) 2017-04-25
KR20090079912A (ko) 2009-07-22
ES2577833T3 (es) 2016-07-19
US9308249B2 (en) 2016-04-12
US20190125853A1 (en) 2019-05-02
JP5898133B2 (ja) 2016-04-06
US20080299152A1 (en) 2008-12-04
EP2601969A3 (en) 2013-08-21
EP2066354A4 (en) 2010-10-20
JP6134364B2 (ja) 2017-05-24
US9861691B2 (en) 2018-01-09
AU2007303608B2 (en) 2013-05-02
EP2601970B1 (en) 2016-10-26
US20160008455A1 (en) 2016-01-14
US8431116B2 (en) 2013-04-30
CA2664157A1 (en) 2008-04-10
ES2618885T3 (es) 2017-06-22
HUE028978T2 (en) 2017-02-28
US7955603B2 (en) 2011-06-07
JP2016020378A (ja) 2016-02-04
US10010599B2 (en) 2018-07-03
PL2601969T3 (pl) 2016-10-31
SG10202012986SA (en) 2021-01-28
EP2641613A1 (en) 2013-09-25
EP2601969A2 (en) 2013-06-12
DK2066354T3 (da) 2013-05-27
WO2008042789A1 (en) 2008-04-10
JP5476544B2 (ja) 2014-04-23
US20130273148A1 (en) 2013-10-17
SG174845A1 (en) 2011-10-28

Similar Documents

Publication Publication Date Title
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
CY1121672T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
CY1120319T1 (el) Πρωτεϊνες συντηξης και εμβολια συνδυασμου που περιλαμβανουν haemophilus influenzae πρωτεϊνη ε και πιλινη α
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1123952T1 (el) Απομονωση και καθαρισμος αντισωματων αντι-il-13 με την χρηση χρωματογραφιας χημικης συγγενειας πρωτεινης α
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
CY1120328T1 (el) Συνθεση εμβολιου περιεχουσα συνθετικο ανοσοενισχυτικο
CY1117331T1 (el) Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων
CY1121934T1 (el) Αντισωματα anti-fcrn
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
CY1120622T1 (el) Μεθοδοι και συνθεσεις για επαγωγη μιας ανοσιακης αποκρισης ως προς egfrviii
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1115932T1 (el) Σκευασμα αντισωματος
MX2018010586A (es) Nanovacuna de activacion de "sting" para inmunoterapia.
CY1111378T1 (el) Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna
CU24058B1 (es) Antagonistas de pcsk9
CY1115999T1 (el) Νεα και ισχυρα mhc- κατηγοριας ιι πεπτιδια που προερχονται απο σουρβιβινη και νευροκανη
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
ECSP066683A (es) Vacuna para mejorar el crecimiento, a base de epítopes neutralizantes
EA201100268A1 (ru) Вакцина
EP2228072A4 (en) CANCER VACCINE COMPOSITION